We use cookies for a better user experience. Read our Privacy Policy

I Agree

Thalassemia Treatment Market

Thalassemia Treatment Market (Treatment Type - Blood Transfusion, Chelating Therapy, Bone Marrow Transplant, and Others (surgery, general medicines)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Thalassemia Treatment Market: Snapshot

The global thalassemia treatment market is pegged to gain significant amount in the form of revenues during the forecast period of 2018 to 2026. One of the major reasons for this prodigious growth is considerable growth in the number of altered thalassemia genes in people from all worldwide locations. Thalassemia is a genetic disorder related to blood. In this disease, patient’s body is not able to produce normal hemoglobin and manufactures a huge number of abnormal red blood cells, which are continuously destroyed. As a result, an individual becomes anemic.

The segmentation of the global thalassemia treatment market is performed on the basis of treatment type and region. Among all treatment options, blood transfusion and chelation therapy are the most popular options used in treating thalassemia patients. Key reasons for this popularity are the cost-effectiveness and easy accessibility than bone marrow transplantation.

The global market for thalassemia treatment is witnessing stupendous growth avenues due to significant growth in the number of blood transfusion and chelation therapy treatments. Apart from this, increased number of bone marrow transplants, rise in number of spleen surgeries, and increased investments in research and development activities are some of the key factors stimulating the growth of the global thalassemia treatment market.

The global thalassemia treatment market is fairly fragmented in nature. Presence of many well-established enterprises connotes high competitive landscape of the market for thalassemia treatment. To lead in this competition, companies working in the thalassemia treatment market are executing various strategic moves such as collaborations and partnerships. Apart from this, they are focused on incorporation of technological advancements in their work processes. A case in point here is recent collaboration announcement by Novartis and Microsoft. Through this collaboration, Microsoft will help Novartis in its medicine transformation using artificial intelligence. Thus, this collaboration will impact positively on the growth of the global thalassemia treatment market in the upcoming period.

Thalassemia Treatment Market - Snapshot

The global thalassemia treatment market is driven by increase in number of altered thalassemia genes across the globe. The global market was valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026 to reach US$ 1,639.6 Mn by 2026. The global market is witnessing high growth owing to increase in blood transfusion and chelation therapy treatments, high number of bone marrow transplants, increase in number of spleen surgeries, and surge in R&D expenditure.

Thalassemia is a genetic blood disorder which produces abnormal hemoglobin in the body. This genetic blood disorder leads to the formation of a large number of red blood cells that are continuously destroyed, which further leads to anemia. The two types of proteins present in the blood of thalassemia patients are alpha globin and beta globin. Alpha thalassemia occurs primarily in people living in Southeast Asia, the Middle East, China, and Africa. Beta thalassemia occurs in people in the Mediterranean origin, and to a lesser extent in people in China, other Asians, and African Americans. Chelation therapy and blood transfusion are the most common treatments for thalassemia patients, as these are cost effective and are easily available compared to bone marrow transplantation. Chelation therapy uses drugs such as deferasirox for the treatment of chronic iron overload occurs during multiple blood transfusions among non-transfusion-dependent thalassemia patients. Chelation therapy drugs used subcutaneous or intravenous with slow infusion technique for purifying blood increase the possibility of curing thalassemia patients.

thalassemia-treatment-market.jpg

Blood transfusion helps patients suffering from alpha thalassemia or beta thalassemia. The transfusion treatment procedure improves overall operational efficiency. High prevalence and incidence rates of thalassemia and rise in number of stem cell transplantations among the global population have resulted in increase in patient flow to private clinics and hospitals. These factors are projected to drive demand for blood transfusion procedure for thalassemia treatment in the near future. Moreover, advancements in gene therapy such as gene editing, stem cell therapy, and proliferation of new drugs for thalassemia treatment are anticipated to fuel the growth of the global thalassemia treatment market from 2018 to 2026.

The global thalassemia treatment market has been segmented based on treatment type and region. In terms of treatment type, the global market has been categorized into blood transfusion, chelating therapy, bone marrow transplant, and others. The chelation therapy segment accounted for major share of the global market in terms of revenue in 2017. The segment is projected to expand at an exponential growth rate during the forecast period. Blood transfusion offers several advantages over bone marrow transplantation such as low cost of treatment. Hence, blood transfusion is gaining popularity among thalassemia patients.

Geographically, the global thalassemia treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to lose market share between 2018 and 2026. The market in North America is primarily driven by rapidly increasing immigrant population from tropical regions, growing number of population with thalassemia carrier gene, and rise in birth rates due to variation of genes among the population in the U.S. Moreover, increase in same community marriage practices and high birth rate of alpha thalassemia patients have been observed in Asia Pacific. This is projected to increase adoption of blood transfusion and chelation therapy treatments during the forecast period. Middle East & Africa is projected to be the fastest growing market for thalassemia treatment during the forecast period. Rest of Middle East & Africa dominated the thalassemia treatment market in the region, while the market in GCC Countries is estimated to expand at an exponential CAGR during the forecast period.

Companies such as bluebird bio, Inc., Acceleron Pharma, Inc., Novartis AG, Celgene Corporation, and Shire plc (Takeda Pharmaceuticals) accounted for the major share of the global thalassemia treatment market in 2016. Celgene Corporation has provided over 525,000 patients with the prescribed Luspatercept medicine. In 2017, the company accelerated 160 trials in approximately 60 indications and more than 25 new molecules have entered preclinical or phase 1 development. Other global players operating in the market include Incyte Corporation, Kiadis Pharma, Gamida Cell, and Bellicum Pharmaceuticals. Companies are adopting the strategy of acquisition and collaboration with parallel companies to improve and strengthen geographic presence in the international market. Moreover, the partnership agreement with companies is expected to increase in number of clinical trials for thalassemia in the near future.

The global thalassemia treatment market has been segmented as given below:

Treatment Type

  • Blood Transfusion
  • Chelation Therapy
  • Bone Marrow Transplantation
  • Others

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • ASEAN Countries
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

    Chapter 1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

    Chapter 2. Assumptions and Research Methodology

    Chapter 3. Executive Summary: Global Thalassemia Treatment Market

    Chapter 4. Market Overview
    4.1. Introduction
           4.1.1. Treatment Type Definition
           4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
           4.3.1. Drivers
           4.3.2. Restraints
           4.3.3. Opportunity
    4.4. Global Thalassemia Treatment Market Analysis and Forecasts, 2016–2026
           4.4.1. Market Revenue Projections (US$ Mn)
    4.5. Porter’s Five Force Analysis
    4.6. Market Outlook
    4.7. Pipeline of Thalassemia Treatment
    4.8. Prevalence & Demography - Thalassemia Disease - by Region/Country
           4.8.1. North America
           4.8.2. Europe
           4.8.3. Asia Pacific
           4.8.4. Latin America
           4.8.5. Middle East & Africa
    4.9. Cost of Treatment-By Region/Country
           4.9.1. North America
           4.9.2. Europe
           4.9.3. Asia Pacific
           4.9.4. Latin America
           4.9.5. Middle East & Africa
    4.10. Prevalent Treatment Regimens - By Country/Region
           4.10.1. Asia Pacific
           4.10.2. Middle East & Africa
    4.11. List of Major Hospitals for Thalassemia Treatment - By Region/ Country/State
           4.11.1. North America
           4.11.2. Europe
           4.11.3. Asia Pacific
           4.11.4. Latin America
           4.11.5. Middle East & Africa
    4.12. Regulatory Scenario, by Region
           4.12.1. North America
           4.12.2. Europe
           4.12.3. Asia Pacific

    Chapter 5. Global Thalassemia Treatment Market Analysis and Forecasts, by Treatment Type
    5.1. Introduction & Definition
    5.2. Key Findings / Developments
    5.3. Market Value Forecast, by Treatment Type, 2016–2026
           5.3.1. Blood Transfusion
           5.3.2. Chelation Therapy
           5.3.3. Bone Marrow Transplant
           5.3.4. Others
    5.4. Market Attractiveness, by Treatment Type

    Chapter 6. Global Thalassemia Treatment Market Analysis and Forecasts, by Region
    6.1. Key Findings
    6.2. Market Value Forecast, by Region
           6.2.1. North America
           6.2.2. Europe
           6.2.3. Asia Pacific
           6.2.4. Latin America
           6.2.5. Middle East & Africa
    6.3. Market Attractiveness, by Country/Region

    Chapter 7. North America Thalassemia Treatment Market Analysis and Forecast
    7.1. Introduction
           7.1.1. Key Findings
    7.2. Market Value Forecast, by Treatment Type, 2016–2026
           7.2.1. Blood Transfusion
           7.2.2. Chelation Therapy
           7.2.3. Bone Marrow Transplant
           7.2.4. Others
    7.3. Market Value Forecast, by Country, 2016–2026
           7.3.1. U.S.
           7.3.2. Canada
    7.4. Market Attractiveness Analysis
           7.4.1. By Treatment Type
           7.4.2. By Country

    Chapter 8. Europe Thalassemia Treatment Market Analysis and Forecast
    8.1. Introduction
           8.1.1. Key Findings
    8.2. Market Value Forecast, by Treatment Type, 2016–2026
           8.2.1. Blood Transfusion
           8.2.2. Chelation Therapy
           8.2.3. Bone Marrow Transplant
           8.2.4. Others
    8.3. Market Value Forecast, by Country/Sub-region, 2016–2026
           8.3.1. Germany
           8.3.2. U.K.
           8.3.3. France
           8.3.4. Spain
           8.3.5. Italy
           8.3.6. Rest of Europe
    8.4. Market Attractiveness Analysis
           8.4.1. By Treatment Type
           8.4.2. By Country/Sub-region

    Chapter 9. Asia Pacific Thalassemia Treatment Market Analysis and Forecast
    9.1. Introduction
           9.1.1. Key Findings
    9.2. Market Value Forecast, by Treatment Type, 2016–2026
           9.2.1. Blood Transfusion
           9.2.2. Chelation Therapy
           9.2.3. Bone Marrow Transplant
           9.2.4. Others
    9.3. Market Value Forecast, by Country/Sub-region, 2016–2026
           9.3.1. China
           9.3.2. India
           9.3.3. ASEAN countries
           9.3.4. Rest of Asia Pacific
    9.4. Market Attractiveness Analysis
           9.4.1. By Treatment Type
           9.4.2. By Country/Sub-region

    Chapter 10. Latin America Thalassemia Treatment Market Analysis and Forecast
    10.1.Introduction
           10.1.1. Key Findings
    10.2.Market Value Forecast, by Treatment Type, 2016–2026
           10.2.1. Blood Transfusion
           10.2.2. Chelation Therapy
           10.2.3. Bone Marrow Transplant
           10.2.4. Others
    10.3.Market Value Forecast, by Country/Sub-region, 2016–2026
           10.3.1. Brazil
           10.3.2. Mexico
           10.3.3. Rest of Latin America
    10.4.Market Attractiveness Analysis
           10.4.1. By Treatment Type
           10.4.2. By Country/Sub-region

    Chapter 11. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast
    11.1.Introduction
           11.1.1. Key Findings
    11.2.Market Value Forecast, by Treatment Type, 2016–2026
           11.2.1. Blood Transfusion
           11.2.2. Chelation Therapy
           11.2.3. Bone Marrow Transplant
           11.2.4. Others
    11.3.Market Value Forecast, by Country/Sub-region, 2016–2026
           11.3.1. GCC countries
           11.3.2. South Africa
           11.3.3. Rest of Middle East & Africa
    11.4.Market Attractiveness Analysis
           11.4.1. By Treatment Type
           11.4.2. By Country/Sub-region

    Chapter 12. Competition Landscape
    12.1.Market Player - Market Presence (2017)
           12.1.1. Current Offerings
           12.1.2. Strategy
    12.2.Company Profiles
           12.2.1. bluebird bio, Inc.
                     12.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                     12.2.1.2. Product Portfolio
                     12.2.1.3. SWOT Analysis
                     12.2.1.4. Financial Overview
                     12.2.1.5. Strategic Overview
           12.2.2. Acceleron Pharma, Inc.
                     12.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                     12.2.2.2. Product Portfolio
                     12.2.2.3. SWOT Analysis
                     12.2.2.4. Financial Overview
                     12.2.2.5. Strategic Overview
           12.2.3. Novartis AG
                     12.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                     12.2.3.2. Product Portfolio
                     12.2.3.3. SWOT Analysis
                     12.2.3.4. Financial Overview
                     12.2.3.5. Strategic Overview
           12.2.4. Celgene Corporation
                     12.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                     12.2.4.2. Product Portfolio
                     12.2.4.3. SWOT Analysis
                     12.2.4.4. Financial Overview
                     12.2.4.5. Strategic Overview
           12.2.5. Shire Plc. (Takeda Pharmaceuticals)
                     12.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                     12.2.5.2. Product Portfolio
                     12.2.5.3. SWOT Analysis
                     12.2.5.4. Financial Overview
                     12.2.5.5. Strategic Overview
           12.2.6. Incyte Corporation
                     12.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                     12.2.6.2. Product Portfolio
                     12.2.6.3. SWOT Analysis
                     12.2.6.4. Financial Overview
                     12.2.6.5. Strategic Overview
           12.2.7. Kiadis Pharma
                     12.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                     12.2.7.2. Product Portfolio
                     12.2.7.3. SWOT Analysis
                     12.2.7.4. Financial Overview
                     12.2.7.5. Strategic Overview
           12.2.8. Bellicum Pharmaceuticals
                     12.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                     12.2.8.2. Product Portfolio
                     12.2.8.3. SWOT Analysis
                     12.2.8.4. Financial Overview
                     12.2.8.5. Strategic Overview
           12.2.9. GlaxoSmithKline plc
                     12.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                     12.2.9.2. Product Portfolio
                     12.2.9.3. SWOT Analysis
                     12.2.9.4. Financial Overview
                     12.2.9.5. Strategic Overview
           12.2.10. Others

    List of Tables

    Table 01: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 02: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, by Region, 2016–2026
    Table 03: North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 04: North America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 05: U.S. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 06: Canada Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 07: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 08: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 09: U.K. Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 10: Germany Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016-2026
    Table 11: France Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 12: Italy Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 13: Spain Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 14: Rest of Europe Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 15: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 16: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 17: India Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 18: China Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 19: ASEAN Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 20: Rest of Asia Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 21: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 22: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 23: Brazil Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 24: Mexico Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 25: Rest of Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 26: Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 27: Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 28: South Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 29: GCC Countries Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026
    Table 30: Rest of Middle East & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2016–2026

    List of Figures

    FIG 01: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, 2016–2026
    FIG 02: Global Thalassemia Treatment Market Value Share, by Region (2017)
    FIG 03: Global Thalassemia Treatment Market Value Share, by Treatment Type (2017)
    FIG 04: Global Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
    FIG 05: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Transfusion, 2017–2026
    FIG 06: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Chelating Therapy, 2017–2026
    FIG 07: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Bone Marrow Transplant, 2017–2026
    FIG 08: Global Thalassemia Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2017–2026
    FIG 09: Global Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
    FIG 10: Global Thalassemia Treatment Market Value Share, by Region, 2018 and 2026
    FIG 11: Global Thalassemia Treatment Market Attractiveness, by Region, 2018–2026
    FIG 12: North America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
    FIG 13: North America Thalassemia Treatment Market Value Share, by Country, 2018–2026
    FIG 14: North America Thalassemia Treatment Market Attractiveness, by Country, 2018–2026
    FIG 15: North America Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
    FIG 16: North America Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
    FIG 17: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
    FIG 18: Europe Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
    FIG 19: Europe Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
    FIG 20: Europe Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
    FIG 21: Europe Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
    FIG 22: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2026
    FIG 23: Asia Pacific Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
    FIG 24: Asia Pacific Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
    FIG 25: Asia Pacific Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
    FIG 26: Asia Pacific Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
    FIG 27: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2026
    FIG 28: Latin America Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
    FIG 29: Latin America Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
    FIG 30: Latin America Thalassemia Treatment Market Value Share, by Treatment Type, 2018 and 2026
    FIG 31: Latin America Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
    FIG 32: Middle east & Africa Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2026
    FIG 33: Middle East & Africa Thalassemia Treatment Market Value Share, by Country/Sub-region, 2018–2026
    FIG 34: Middle East & Africa Thalassemia Treatment Market Attractiveness, by Country/Sub-region, 2018–2026
    FIG 35: Middle East & Africa Thalassemia Treatment Market Value Share, by Treatment Type , 2018 and 2026
    FIG 36: Middle East & Africa Thalassemia Treatment Market Attractiveness, by Treatment Type, 2018–2026
    FIG 37: Global Thalassemia Treatment Market Performance, by Company, 2017
    FIG 38: bluebird bio, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
    FIG 39: bluebird bio, Inc., Research & Development (US$ Mn) – Company Level, 2014–2017
    FIG 40: bluebird bio, Inc., Breakdown of Revenue Generation (US$ Mn), by Collaboration, 2014-2017
    FIG 41: bluebird bio, Inc., Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
    FIG 42: Acceleron Pharma, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
    FIG 43: Acceleron Pharma, Inc., Research & Development (US$ Mn) – Company Level, 2014–2017
    FIG 44: Acceleron Pharma, Inc., Breakdown of Revenue Generation (US$ Mn), by Collaboration, 2014-2017
    FIG 45: Acceleron Pharma, Inc., Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
    FIG 46: Novartis AG, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
    FIG 47: Novartis AG, Research & Development (US$ Mn) and Marketing & Sales (US$ Mn)– Company Level, 2016–2017
    FIG 48: Novartis AG, Net Sales (%), by Oncology Business Units, 2017
    FIG 49: Novartis AG, Net Sales (%), by Business Segment, 2017
    FIG 50: Incyte Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
    FIG 51: Incyte Corporation, Research & Development (US$ Mn) – Company Level, 2014–2017
    FIG 52: Incyte Corporation, Breakdown of Revenue Generation (US$ Mn), by Royalties, 2014-2017
    FIG 53: Incyte Corporation, Breakdown of Sales (%), by Products, 2017
    FIG 54: Kiadis Pharma, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
    FIG 55: Kiadis Pharma, Research & Development (US$ Mn) – Company Level, 2014–2017
    FIG 56: Kiadis Pharma, Breakdown of Revenue Generation (US$ Mn), by Operating and Investing Activities, 2016-2017
    FIG 57: Kiadis Pharma, Breakdown of Operating Cost to Company (%), 2016 and 2017
    FIG 58: Shire plc, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
    FIG 59: Shire plc, Research & Development (US$ Mn) – Company Level, 2014–2017
    FIG 60: Shire plc, Breakdown of Revenue Generation (%), by Region/Country, 2017
    FIG 61: Shire plc, Breakdown of Product Sales to Company (%), 2017
    FIG 62: Celgene Corporation, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
    FIG 63: Celgene Corporation, Research & Development (US$ Mn) – Company Level, 2014–2017
    FIG 64: Celgene Corporation, Breakdown of Revenue Generation (US$ Mn), by Region, 2015-2017
    FIG 65: Celgene Corporation, Net Sales(%), by Products, 2017
    FIG 66: Bellicum Pharmaceuticals, Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
    FIG 67: Bellicum Pharmaceuticals, Research & Development (US$ Mn) – Company Level, 2014–2017
    FIG 68: Bellicum Pharmaceuticals, Breakdown of Revenue Expenses (US$ Mn), by Collaboration and License Agreement, 2014-2017
    FIG 69: Bellicum Pharmaceuticals, Breakdown of R&D Cost to Company (%), by Products in Pipeline, 2017
    FIG 70: GlaxoSmithKline Plc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2014-2017
    FIG 71: GlaxoSmithKline Plc., Research & Development (US$ Mn) – Company Level, 2014–2017
    FIG 72: GlaxoSmithKline Plc., Breakdown of Revenue Generation (US$ Mn), by Products, 2014-2017
    FIG 73: GlaxoSmithKline Plc., Breakdown of Sales(%), by Region, 2017

Google translate

Copyright © Transparency Market Research, Inc. All Rights reserved